StockData
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc. (CAPR) stock

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$9.53−0.71 (-6.93%)

Close on Nov 13, 2026Market cap $554.07MP/E –Yield –

Earnings

Capricor Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.73
-$0.54 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Capricor Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close––-$0.73Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close––-$0.70Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close––-$0.59Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close$0-100.0%-$0.62Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025after the close$0-100.0%-$0.54Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$0-100.0%-$0.57Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close$0-100.0%–Release
Q4 FY2024ended Dec 31, 2024Mar 19, 2025after the close$11.10M-8.3%–Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024after the close$2.30M-62.9%-$0.38Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$4.00M+2.6%-$0.35Release
Q1 FY2024ended Mar 31, 2024May 13, 2024after the close$4.90M+63.3%-$0.31Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Capricor Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Capricor Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Capricor Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
    Results
  2. Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
    News
  3. Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    Results
  4. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
    News
  5. The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
    News
  6. Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
    News
  7. Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Results
  8. Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
    Update
  9. 8-K exhibit EX-99.2
    Update
  10. Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    Results
  11. Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
    Update
  12. Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
    Update
  13. Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside
    Update
  14. Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
    Update
  15. Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Results

See a number that looks wrong?